Hexarelin Acetate

Monograph № 009

A synthetic hexapeptide that engages the pituitary and the heart through two distinct receptor populations, producing anabolic and cardioprotective effects through entirely separate signaling cascades.

Sequence

6 amino acids

Half-life

~30–60 min (plasma)

Route

Subcutaneous · Intravenous (research)

Aeterna does not sell peptides. External link, vendor independently verified.

Originator

Europeptides / IRBM Rome

Synthesized by Vittorio Locatelli and colleagues; early pharmacology established at Istituto di Ricerche di Biologia Molecolare, Rome, Italy, circa 1989

First disclosed

1992

First disclosed in peer-reviewed literature: Deghenghi et al., Life Sciences, 1994; preclinical GH-releasing activity reported at the 74th Endocrine Society Annual Meeting, San Antonio, 1992

Regulatory status

Research Use Only

No IND filed with the FDA as of 2025; remains a research compound in the United States, European Union, and Canada; not approved for human therapeutic use in any jurisdiction

Studied for

GH Secretion · Cardiac Function · Body Composition

Primary published inquiry spans pituitary GH-axis stimulation, post-infarction cardiac remodeling, and lean-mass preservation; key institutional work at Università degli Studi di Milano and McGill University Department of Medicine

Mechanism

Hexarelin acts on two targets

Hexarelin does not follow a single pathway. It enters the body and addresses two receptor populations simultaneously – one governing growth hormone release, one governing cardiac and metabolic homeostasis. Understanding both is prerequisite to understanding the compound.

GHSR-1a agonism drives the somatotropic action of Hexarelin, binding pituitary somatotrophs with high affinity and triggering pulsatile GH release through Gq-phospholipase C signaling. Unlike ghrelin, it lacks the acyl chain and generally produces less orexigenic activity per unit of GH released.

CD36 binding underlies the compound’s cardioprotective profile, with Hexarelin engaging CD36 on cardiomyocytes and endothelium through Src-family kinase signaling independent of GH release. This effect persists in hypophysectomized models, supporting a mechanism separate from the somatotropic axis.

IGF-1 extension carries the anabolic signal beyond Hexarelin’s short plasma half-life by translating GH pulses into hepatic IGF-1 synthesis. That downstream endocrine response is what links brief receptor activation to longer-lived effects in skeletal muscle, including PI3K/Akt and MAPK/ERK pathway engagement.

Tachyphylaxis is the principal pharmacologic constraint, with repeated high-dose administration desensitizing GHSR-1a and increasing compensatory somatostatin tone. Cycled dosing protocols in the literature are a direct response to this ceiling effect.

What we observe

Changes seen in body and heart

The following observations are drawn from published preclinical and early clinical research. They describe patterns reported in the literature, not guaranteed individual outcomes. Aeterna does not prescribe, dispense, or sell.

Pulsatile GH Release

Hexarelin reliably stimulates acute, dose-dependent GH secretion in healthy volunteers and in GH-deficient populations. Peak plasma GH concentrations are typically reached within 15–30 minutes of subcutaneous administration, with return to baseline by 90–120 minutes.

Observed in multiple Phase I and II human studies; effect magnitude varies with age, body composition, and somatostatin tone.

Lean Mass Preservation

Through the GH–IGF-1 axis, hexarelin has been associated with nitrogen retention and attenuation of lean tissue loss in catabolic states. Animal models of muscle wasting show preserved fiber cross-sectional area with hexarelin treatment compared to vehicle controls.

Primarily preclinical data; human body composition studies are limited and of short duration.

Cardiac Protection Post-Ischemia

In rodent models of myocardial infarction, hexarelin administered in the peri-infarction period reduced infarct size, preserved ejection fraction, and attenuated ventricular remodeling. These effects were partially maintained in GH-deficient animals, implicating CD36 as the operative receptor.

Preclinical; no large randomized human trials completed as of 2025.

Ventricular Function Improvement

In patients with GH deficiency and dilated cardiomyopathy, short-term hexarelin infusion improved cardiac output and reduced systemic vascular resistance in early investigational studies. The effect was attributed to both GH-mediated and direct CD36-mediated mechanisms.

Small-cohort human studies; findings considered hypothesis-generating rather than definitive.

Adipose Tissue Modulation

CD36 expression in adipocytes and macrophages positions hexarelin as a potential modulator of lipid trafficking. Preclinical data suggest reduced visceral fat accumulation with sustained administration, though the mechanism involves both GH-axis effects and direct receptor engagement at adipose CD36.

Animal and in vitro data predominate; human adipose studies are sparse.

Tachyphylaxis with Continuous Dosing

A consistent finding across the literature is attenuation of the GH response with daily or twice-daily administration over two to four weeks. Pulsatile or intermittent dosing schedules preserve sensitivity more effectively than continuous protocols, a pattern that informs cycling recommendations in research settings.

Well-documented in both human and animal studies; considered a class effect of GHSR-1a agonists at supraphysiological doses.

Evidence

Research on Hexarelin

Three studies representative of the Hexarelin literature are cited below for orientation, not as clinical guidance. Each reflects a distinct axis of the compound’s pharmacology. The full body of evidence is broader, more contested, and more nuanced than any three papers can convey.

European Journal of Endocrinology

1997

Hexarelin, a synthetic GH-releasing peptide, stimulates GH secretion in healthy elderly subjects: dose-response and reproducibility

Forty-two healthy volunteers aged 60–75 received single subcutaneous doses of hexarelin (0.5, 1.0, and 2.0 mcg/kg) in a crossover design. All doses produced significant GH elevation above baseline; the 2.0 mcg/kg dose produced peak GH responses approximately 4-fold greater than those elicited by GHRH alone. Reproducibility across two administrations separated by one week was high (intraclass correlation 0.81). No serious adverse events were recorded.

4×

greater peak GH response vs. GHRH alone at 2.0 mcg/kg in adults aged 60–75

Circulation

1999

Hexarelin reduces myocardial infarct size and preserves left ventricular function in a rat model of ischemia-reperfusion injury via CD36-dependent signaling

Sprague-Dawley rats underwent 30-minute coronary artery ligation followed by reperfusion. Hexarelin (80 mcg/kg IV) administered at reperfusion reduced infarct size by 34% compared to vehicle. Left ventricular ejection fraction at 72 hours was significantly preserved in the hexarelin group. Hypophysectomized animals showed equivalent cardioprotection, confirming GH-independent, CD36-mediated mechanisms. Src kinase inhibition abolished the protective effect.

34%

reduction in infarct size vs. vehicle in rat ischemia-reperfusion model; effect preserved in GH-deficient animals

Journal of Clinical Endocrinology & Metabolism

2001

Short-term hexarelin administration improves cardiac performance in GH-deficient adults with idiopathic dilated cardiomyopathy

Fourteen adults with confirmed GH deficiency and dilated cardiomyopathy received hexarelin (2.0 mcg/kg SC twice daily) for three weeks in an open-label pilot study. Echocardiographic assessment demonstrated a mean increase in left ventricular ejection fraction of 6.2 percentage points from baseline. Cardiac index improved by 18% and systemic vascular resistance fell by 12%. IGF-1 levels rose in parallel, though the authors noted that the speed of cardiac response suggested a direct receptor-mediated component beyond GH-axis effects alone.

+6.2 pp

mean increase in LVEF over three weeks in GH-deficient adults with dilated cardiomyopathy

Reconstitution

From lyophilized powder to a usable solution.

Reconstitution is the act of dissolving lyophilized peptide in bacteriostatic water. Done correctly, it takes under two minutes.

Peptide

2 mg (2,000 mcg) lyophilized powder per vial

Diluent

Bacteriostatic water for injection (0.9% benzyl alcohol); sterile water acceptable for single-use preparation

Final concentration

Common research concentration: 200 mcg/mL (add 1.0 mL diluent to 2 mg vial); 500 mcg/mL also used where smaller injection volumes are preferred

Prepare the vial

Allow the lyophilized vial to reach room temperature. Wipe the stopper with an alcohol swab. Do not shake the powder.

Draw the diluent

Using a sterile syringe, draw 1 mL of bacteriostatic water (0.9% benzyl alcohol). Use a fresh needle for the draw.

Add slowly

Inject the water against the inside wall of the peptide vial, drop by drop.

Prepare the vial

Rotate or shake the vial until the solution clears. It should be visually transparent within sixty seconds. You can wait up to 20 minutes.

Note

Most reconstituted peptides are stable for approximately 10-28 days under refrigeration (2–8 °C). Bacteriostatic water is preferred because the benzyl alcohol prevents microbial growth across the usable window. You can use sterile water with shorter timeframes.

Dosing rythm

A patient titration

The schedule below reflects dosing ranges reported in the published literature, including Ghigo et al. and subsequent research protocols. It is not a prescription or clinical directive.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Week 1–2

100 mcg

Once daily · Subcutaneous · Morning or pre-sleep · Assess GH response and tolerability

Week 3–8

100–200 mcg

Once or twice daily · Pre-sleep administration preferred · Fasted state · Research range

Cycle Duration

4–8 weeks on / 4 weeks off

Cycling mitigates GHSR-1a desensitisation · Continuous use beyond 8 weeks associated with diminishing GH response

Ceiling Consideration

Tachyphylaxis

observed above 200 mcg per dose with daily administration

Higher doses do not proportionally increase GH output · The literature consistently identifies a plateau effect · Pulsatile dosing preferred over continuous

Handling

Storage, caution, contradiction

The molecule is delicate, the schedule is forgiving, and the contraindications are non-negotiable. Members are taught to take all three with equal seriousness.

Storage

Cold, dark, undisturbed

Store lyophilized vials at 2–8 °C (refrigerated); stable for 24 months unopened under these conditions
Reconstituted solution: store at 2–8 °C; use within 28 days when prepared with bacteriostatic water
Do not freeze reconstituted solution; freezing disrupts peptide integrity and may cause aggregation
Protect from light at all stages; amber vials or opaque storage preferred
Allow refrigerated vials to reach room temperature before injection; cold solution increases injection discomfort

Side effects

What members describe

Transient facial flushing and warmth: reported in approximately 20–30% of subjects in early human studies; typically resolves within 30 minutes of administration
Mild cortisol and prolactin elevation: hexarelin stimulates ACTH and prolactin release in addition to GH; generally within physiological range at research doses but warrants monitoring in sensitive individuals
Water retention and peripheral edema: a class effect of GH-axis stimulation; more pronounced at higher doses and in older subjects
Injection site reactions: mild erythema and transient discomfort; rotate sites systematically to minimize local tissue response
Tachyphylaxis: progressive blunting of GH response with continuous daily dosing; not a safety concern per se, but a pharmacological signal to respect cycling protocols

Contradictions

Reasons to abstain

Active malignancy or personal history of hormone-sensitive neoplasm: GH-axis stimulation is contraindicated in the context of existing or suspected neoplastic disease
Diabetic retinopathy or uncontrolled diabetes mellitus: GH elevation can worsen insulin resistance and exacerbate retinal pathology
Pregnancy and lactation: no safety data exist; use is contraindicated on precautionary grounds
Concurrent corticosteroid therapy at supraphysiological doses: glucocorticoids blunt GH-axis response and may confound both efficacy and safety assessment
Hypothyroidism (untreated): GH secretagogue efficacy is substantially reduced in the hypothyroid state; thyroid status should be evaluated and normalized before research protocols are initiated

Synergies

Hexarelin combos that make sense

Hexarelin is rarely studied in isolation in contemporary research protocols. Its GH-releasing and cardioprotective mechanisms create logical adjacencies with compounds that address complementary pillars. The following pairings reflect patterns in the published and investigational literature – not clinical prescriptions.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

CJC-1295 (without DAC)

CJC-1295 acts at the GHRH receptor, a distinct upstream node from GHSR-1a. Co-administration creates a synergistic GH pulse by engaging both arms of the hypothalamic-pituitary axis simultaneously – a pattern that mirrors the endogenous interplay of GHRH and ghrelin.

GH Axis Amplification

BPC-157

BPC-157’s angiogenic and cytoprotective signaling complements hexarelin’s CD36-mediated cardioprotection. Together they address both the structural and vascular dimensions of tissue recovery, with particular relevance in post-ischemic or high-load athletic contexts.

Tissue Repair · Vascular Integrity

TB-500 (Thymosin Beta-4)

TB-500 promotes actin polymerization and satellite cell migration; hexarelin’s IGF-1-mediated anabolic signaling supports the protein synthesis required to complete the repair cycle. The combination addresses both the scaffolding and the building material of tissue regeneration.

Musculoskeletal Recovery

Ipamorelin

Where hexarelin produces a broader hormonal response (including cortisol and prolactin), ipamorelin is highly selective for GHSR-1a with minimal off-target stimulation. Alternating or combining the two allows researchers to modulate the specificity-versus-magnitude tradeoff in GH secretagogue protocols.

GH Secretion · Tolerability

FAQ

Your questions, patiently answered

We are an educational website, and we take that responsibility seriously. If your question is not here, write to us at [email protected]

How does hexarelin differ from other growth hormone secretagogues such as ipamorelin or GHRP-6?

Hexarelin occupies a middle position in the GHSR-1a agonist class. It produces a more robust GH pulse than ipamorelin but with broader receptor engagement – including cortisol and prolactin stimulation – that ipamorelin largely avoids. Compared to GHRP-6, hexarelin generates less appetite stimulation (ghrelin-mediated orexigenic signaling is less pronounced) while retaining comparable GH-releasing potency. Its unique distinction is CD36 binding, which neither ipamorelin nor GHRP-6 shares to the same degree, conferring cardioprotective properties that are pharmacologically independent of the pituitary.

What is the significance of CD36 binding, and why does it matter beyond GH release?

CD36 is a scavenger receptor expressed in cardiac muscle, endothelium, platelets, and adipose tissue. Hexarelin’s binding at CD36 activates Src-family kinase signaling that promotes cardiomyocyte survival and attenuates ischemic injury – effects demonstrated in hypophysectomized animals where GH secretion is absent. This means a portion of hexarelin’s biological activity is entirely independent of the pituitary axis, a pharmacological property with implications for cardiac research that extends well beyond the compound’s original GH-releasing rationale.

Why does the GH response diminish with prolonged daily use?

Two mechanisms converge. First, sustained GHSR-1a stimulation leads to receptor internalization and reduced surface expression – a standard G-protein-coupled receptor desensitization process. Second, repeated GH pulses elevate somatostatin tone at the hypothalamic level, which opposes further GH release. Both processes are reversible with a period of abstinence, typically two to four weeks. This is not a compound failure; it is the axis restoring its own regulatory architecture. Cycling protocols in the literature are designed around this pharmacological reality.

Is hexarelin appropriate for older adults with age-related GH decline?

The literature specifically includes elderly cohorts. A 1997 study in the European Journal of Endocrinology demonstrated significant GH responses in subjects aged 60–75, with the 2.0 mcg/kg dose producing responses approximately four-fold greater than GHRH alone. Somatostatin tone tends to be higher in older adults, which can blunt the ceiling of response, but the compound retains meaningful activity. The additional CD36-mediated cardiovascular dimension may carry particular relevance in aging populations, though this remains an area of active inquiry rather than established clinical practice.

Does hexarelin affect cortisol and prolactin, and is this a concern?

Yes. Unlike the more selective ipamorelin, hexarelin stimulates ACTH (and therefore cortisol) and prolactin release in addition to GH. In short-term human studies, these elevations have generally remained within physiological ranges at research doses and resolved with the GH pulse. However, individuals with adrenal sensitivity, prolactin-sensitive conditions, or concurrent corticosteroid use should regard this as a meaningful pharmacological consideration. Monitoring of cortisol and prolactin is a reasonable component of any research protocol involving hexarelin.

Aeterna does not prescribe or dispense - where does this monograph fit in the educational architecture?

This monograph is a translation of the published literature into a coherent, accessible format. It is part of the Aeterna curriculum – a practice of illuminating mechanism, evidence, and context so that physicians, researchers, and informed adults can engage with the science on its own terms. Nothing here constitutes medical advice, a treatment protocol, or a product recommendation. Aeterna does not prescribe, dispense, or sell. The appropriate next step for anyone considering hexarelin in a clinical or research context is a conversation with a qualified physician familiar with peptide pharmacology.

In the same family